RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Column Group LLC

Column Group LLC trimmed its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 50.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,328,613 shares of the company's stock after selling 1,352,008 shares during the period. RAPT Therapeutics makes up approximately 3.8% of Column Group LLC's holdings, making the stock its 4th largest holding. Column Group LLC owned approximately 3.80% of RAPT Therapeutics worth $2,099,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC lifted its holdings in shares of RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company's stock worth $79,000 after acquiring an additional 29,195 shares during the period. JPMorgan Chase & Co. lifted its stake in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock worth $34,000 after purchasing an additional 25,130 shares during the period. SG Americas Securities LLC lifted its stake in RAPT Therapeutics by 401.9% during the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock worth $84,000 after purchasing an additional 42,636 shares during the period. Medicxi Ventures Management Jersey Ltd acquired a new stake in RAPT Therapeutics during the fourth quarter valued at approximately $35,316,000. Finally, Los Angeles Capital Management LLC grew its stake in shares of RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock valued at $348,000 after purchasing an additional 18,558 shares during the period. Institutional investors and hedge funds own 99.09% of the company's stock.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT traded down $0.03 during trading on Friday, reaching $0.77. The stock had a trading volume of 734,481 shares, compared to its average volume of 1,268,762. The stock has a market capitalization of $101.65 million, a PE ratio of -0.28 and a beta of -0.04. RAPT Therapeutics, Inc. has a 52 week low of $0.75 and a 52 week high of $4.83. The business's 50-day moving average price is $1.03 and its 200 day moving average price is $1.26.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. Analysts forecast that RAPT Therapeutics, Inc. will post -2.14 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of RAPT Therapeutics in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.